We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: clinical trials
MedXY News
EnglishTag

clinical trials

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
Hematology-Oncologyclinical trialsoncology

Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care

By MedXY|Dec 22, 2025

A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con

Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I
CardiologyCardiologyclinical trials

Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Dec 21, 2025

A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedu

Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line
Internal Medicineclinical trialsEvidence-Based Medicine

Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line

By MedXY|Dec 20, 2025

A systematic review of 347 randomized trials reveals that non-industry-sponsored trials lag significantly behind industry counterparts in registration and results publication, with nearly one-third of all trials discontinued prematurely due

NeurologyAzathioprineclinical trials

Azathioprine in Early Parkinson’s Disease: Trial Fails Primary Endpoint but Reveals Sex-Specific Immune Signals

By MedXY|Dec 19, 2025

The AZA-PD phase 2 trial found that while azathioprine was well-tolerated in early Parkinson’s disease, it did not significantly improve gait-axial scores. However, exploratory data suggests potential motor benefits in female patients

Hematology-Oncologyclinical trialsmeasurable residual disease

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

By MedXY|Dec 19, 2025

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep

Hematology-Oncologyclinical trialsgene therapy

Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B

By MedXY|Dec 19, 2025

The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph

Stage-specific Tau-PET Dynamics in Biological Alzheimer’s Disease: Implications for Trial Design and Outcome Selection
NeurologyAlzheimer's diseasebiomarkers

Stage-specific Tau-PET Dynamics in Biological Alzheimer’s Disease: Implications for Trial Design and Outcome Selection

By MedXY|Dec 13, 2025

Longitudinal tau-PET accumulation follows distinct regional patterns across biological AD stages; aligning trial inclusion and outcome ROIs to baseline tau stage can substantially reduce sample sizes and improve power for disease-modifying

NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era
newsBiochemical Recurrenceclinical trials

NCI Working Group on Biochemically Recurrent Prostate Cancer: Trial Design Guidance for a PSMA Era

By MedXY|Dec 8, 2025

The NCI convened experts to provide clinical-trial design recommendations for biochemically recurrent prostate cancer in the era of PSMA PET, defining PSMA+BCR, high-risk criteria, imaging and data standards, endpoint suggestions, and a pus

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
newsclinical trialscognitive impairment

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

By MedXY|Nov 30, 2025

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological chall

Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise
Dermatologyclinical trialsDelphi consensus

Standardizing How Clinicians See Hidradenitis Suppurativa: Key Consensus on Lesion Definitions and Investigator Guidance from a Modified Delphi Exercise

By MedXY|Nov 27, 2025

An international Delphi consensus produced standardized morphological definitions and practical guidance to improve investigator lesion assessment in hidradenitis suppurativa clinical trials, enhancing reliability and trial data quality.

Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus
Dermatologyclinical trialsDelphi consensus

Standardizing How Investigators Identify Hidradenitis Suppurativa Lesions: Key Findings from a Modified Delphi Consensus

By MedXY|Nov 27, 2025

A multidisciplinary Delphi panel produced consensus morphological definitions and practical guidance to standardize investigator lesion assessments in hidradenitis suppurativa (HS) clinical trials — improving reliability of endpoints such a

What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials
newsclinical trialslong COVID

What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials

By MedXY|Nov 23, 2025

A concise guide to the newly published Core Outcome Set for Post COVID-19 Condition (COS‑PCC): the nine prioritized outcomes, recommended measurement instruments, timing considerations, and implications for research and care.

DEN-CORE: An international consensus COMS to standardise dengue clinical trials
Infectious Diseasesclinical trialsDengue

DEN-CORE: An international consensus COMS to standardise dengue clinical trials

By MedXY|Nov 23, 2025

An international Delphi consensus defined a Core Outcome Measurement Set (COMS) for dengue trials to harmonise outcome selection and measurement across settings, improving comparability and evidence synthesis.

Most Host Countries Don’t Get Timely Access to Medicines They Help Test: An Analysis of FDA-Supported Trials (2015–2018)
newsclinical trialshealth equity

Most Host Countries Don’t Get Timely Access to Medicines They Help Test: An Analysis of FDA-Supported Trials (2015–2018)

By MedXY|Nov 18, 2025

A cross-sectional analysis (FDA approvals 2015–2018) found that most countries hosting pivotal trials lack timely market authorization for tested medicines, especially lower- and middle-income countries—raising ethical, regulatory, and poli

Modernizing AML Trial Eligibility Boosts Enrollment and Equity: Safety-Based Criteria Could Double Participation
Hematology-Oncologyacute myeloid leukemiaclinical trials

Modernizing AML Trial Eligibility Boosts Enrollment and Equity: Safety-Based Criteria Could Double Participation

By MedXY|Nov 17, 2025

Applying safety-focused, modernized eligibility criteria to historical AML trials increased patient eligibility from a median of 48% to 84% and reduced racial/ethnic disparities, suggesting pragmatic pathways to improve enrollment and repre

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy
newsclinical trialshepatocellular carcinoma

Navigating Non-Proportional Hazards in Hepatocellular Carcinoma Trials: Enhancing Interim Analysis Accuracy

By MedXY|Oct 28, 2025

Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making

Revolutionizing Spinocerebellar Ataxia Assessment: The Novel Digital Composite Balance Score SIBA
Neurologyclinical trialsSpinocerebellar ataxia

Revolutionizing Spinocerebellar Ataxia Assessment: The Novel Digital Composite Balance Score SIBA

By MedXY|Oct 19, 2025

The Score of Integrated Balance in Ataxia (SIBA) is a newly developed digital composite score that accurately measures standing and walking balance in spinocerebellar ataxia, enabling smaller, more efficient clinical trials with improved se

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
AIclinical trialsfibrosis

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology

By MedXY|Oct 8, 2025

AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials
PsychiatryBehavioral therapybuprenorphine

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials

By MedXY|Oct 7, 2025

A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use d

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials
Clinical Updatescancerclinical trials

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY|Oct 6, 2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide ther

Prev
4 / 5
12345
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities